Mounjaro: opinions, realistic expectations and what the leaflet says

Individual opinions about Mounjaro vary enormously, and this is not an inconsistency in the accounts but exactly what the authorisation trial predicts: the average weight loss was 15.0% at the 5 mg dose and 20.9% at 15 mg after 72 weeks, but group averages hide considerable individual variation. The approved product document describes the same things without the emotional intensity of a forum: indications, side effects by frequency, contraindications.

We do not publish testimonials and we do not show before-and-after photos. This text compares what is discussed with what is documented.

What does the approved document say?

The official product information is published by the European Medicines Agency, on the Mounjaro page. The document covers the authorised indications, the method of administration, contraindications, special warnings and the complete list of side effects with their frequencies.

What you will not find there, and it is good to know in advance: it does not promise a number of kilograms, does not guarantee a result and does not describe the subjective experience of the treatment. An authorisation document describes what was measured, not how it feels.

The active substance is tirzepatide, a dual agonist — it acts on both the GLP-1 receptor and the GIP receptor. It is given subcutaneously, usually once a week. The dose and the administration schedule are set solely by the prescribing doctor; we do not discuss them here.

How much weight is lost, in figures?

The data come from SURMOUNT-1, published in the New England Journal of Medicine in 2022. In the trial, more than 85% of participants in each treatment arm reached a loss of at least 5% of their starting weight.

For comparison, semaglutide 2.4 mg produced an average weight loss of 14.9% at 68 weeks in STEP-1. The two trials did not compare the substances directly with each other, so the difference between the figures is not a head-to-head result.

Why do opinions on forums differ so much?

There are four explanations, and none of them assumes that anyone is lying.

• Averages hide variation. An average weight loss of 20.9% means that some lost much more, others much less. A forum gathers the extremes, because the extremes are what is worth telling.
• The timing of the account differs. An opinion written in week 6 and one written in week 60 describe different parts of the same curve. The first is almost always more enthusiastic or more frightened.
• Dose and duration differ, and they almost never appear in the account.
• The context differs. In the trial, all participants received advice on diet and physical activity. In real life, this varies completely.

To which a simple filter is added: people with an unremarkable experience do not write about it. Forums are, structurally, a collection of non-averages.

Which side effects do people report most often?

The same ones the approved document classifies as most common — nausea, diarrhoea, vomiting, constipation, abdominal pain, decreased appetite — appearing mainly at the start and after a dose increase. Here the forums and the leaflet do not contradict each other; only the tone differs.

What is discussed on forums and is not a source of guidance: what to take for nausea, how to "get through" the first weeks, when to adjust something. The details of what is common, what passes on its own and what calls for immediate contact with the doctor are in the article on side effects.

What gets repeated on forums, and what does the document say?

A few claims circulate so often that they have become folklore. Alongside them, what is documented.

The table is not a list of "myths debunked". Some claims on forums are accurate observations by people describing what happened to them. The problem is not their sincerity but the generalisation: an individual experience does not become a rule through repetition.

What expectations are realistic?

Three statements that honestly summarise the data:

Most people in the trials lost a significant amount of weight, and the average loss at the highest dose exceeded 20% of starting weight after 72 weeks.

Your result may differ from the average, in either direction, and this cannot be predicted in advance.

The interval matters more than anything. Anyone who judges after eight weeks is judging roughly 11% of the length of the trial.

And a fourth, the one most often left out: what happens when you stop. Withdrawal studies show a substantial regain of the weight lost — we have covered it separately, with figures, in how long Mounjaro is taken and what happens when you stop. If the scales are standing still and you are wondering why, the structured answers are in the article on why I am not losing weight on Mounjaro.

In short

• In the SURMOUNT-1 trial, the average weight loss after 72 weeks was 15.0% at the 5 mg dose and 20.9% at 15 mg, compared with 3.1% in the placebo group.
• More than 85% of participants in each treatment arm reached a loss of at least 5% of their starting weight.
• Individual opinions vary because group averages hide real variation, and forums structurally gather the extreme experiences.
• The approved product document describes indications, contraindications and side effects by frequency, but does not promise a number of kilograms.
• The dose and the administration schedule are set solely by the prescribing doctor, never on the basis of an experience reported by someone else.

This article is for information only and does not replace a medical consultation. We do not publish patient testimonials and we do not prescribe prescription medicines.